Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Controversial Drug
In March 2025, Roche entered into an outstanding licensing agreement and collaboration with Zealand Pharma for co-commercializing and co-developing petrelintide as a standalone therapy and a fixed-dose combination with Roches lead incretin asset CT-388
Personalized Medical Oversight: Your health is our top priority
F., & STEP 1 Study Group (2021)
The risks of grey market retatrutide include: Underdosed product: A vial labeled 10mg may contain significantly less, making your carefully planned protocol ineffective Contamination: Bacterial contamination in improperly manufactured peptides can cause serious infections Mislabeled compounds: What you think is retatrutide may be a different peptide entirely No recourse: If you experience adverse effects from a grey market product, there is no regulatory body to report to and no manufacturer accountability Current retatrutide availability is limited compared to semaglutide and tirzepatide
US$ 23.02
US$ 27.44
US$ 21.68
